Literature DB >> 16580179

Immunohistochemical expression of glucocorticoid and calcitonin receptors as a tool for selecting therapeutic approach in central giant cell granuloma of the jawbones.

M Vered1, A Buchner, D Dayan.   

Abstract

Aggressive cases of central giant cell granuloma (CGCG) have been arbitrarily treated with steroids and calcitonin. The aim of this study was to develop a practical tool, based on the relative percentage of positively stained cells for glucocorticoid and/or calcitonin receptors, for selecting the appropriate therapeutic agents to treat CGCG. Forty-one formalin-fixed, paraffin-embedded blocks of CGCG were immunohistochemically stained for glucocorticoid and calcitonin receptors. Percentage of positive lesional mononuclear and giant cells was estimated for each case. Intense staining was considered as staining 50% or more of the cells. Correlations among staining scores were analysed by Spearman's test. All cases stained for glucocorticoid receptor. Heterogeneity among cases showed as intense staining in both cell types (21 lesions), in only one cell type (13 lesions) and weakly in both cell types (7 lesions). Only 23 cases demonstrated staining for calcitonin receptor, of which 15 stained intensely in both cell types and 7 in only one cell type. Among staining scores of both receptors, no significant statistical correlation was found (P>0.05). It can therefore be suggested that the relative percentage of immunohistochemically stained mononuclear and giant cells for glucocorticoid and/or calcitonin receptors can serve as a reliable and practical tool for selecting the appropriate therapeutic agent to treat CGCG. The clinical application of this method should be assessed in well controlled clinical studies, especially in cases of aggressive lesions, before initiating and during therapeutic treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580179     DOI: 10.1016/j.ijom.2006.02.014

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  8 in total

1.  Clinico-pathologic conference AAOMP/IAOP 2008: case 3.

Authors:  M Vered; I O Bello; T Salo; I Allon
Journal:  Head Neck Pathol       Date:  2008-09-13

2.  Central Giant Cell Granuloma Treated with Intralesional Corticosteroid Injections and Bisphosphonates: A Long-Term Follow-Up Case Study.

Authors:  Raíssa Pinheiro de Mendonça; Geovanni Pereira Mitre; Flavio Henrique Real; Maria Sueli da Silva Kataoka; Sérgio de Melo Alves Júnior; Paulo Vianna; Newton Guerreiro Da Silva Júnior; João de Jesus Viana Pinheiro
Journal:  Head Neck Pathol       Date:  2019-07-11

3.  Treatment Challenges with Benign Bone Tumors of the Orbit.

Authors:  Helen Merritt; Vivian T Yin; Margaret L Pfeiffer; Wei-Lien Wang; Matthew C Sniegowski; Bita Esmaeli
Journal:  Ocul Oncol Pathol       Date:  2015-02-10

Review 4.  Aggressive giant cell granuloma of the jaws treated with interferon alpha: a report of two cases.

Authors:  J E O'Connell; G J Kearns
Journal:  Ir J Med Sci       Date:  2012-10-26       Impact factor: 1.568

5.  Brown tumor in mandible as a first sign of vitamin D deficiency: A rare case report and review.

Authors:  K V Arunkumar; Sanjeev Kumar; D Deepa
Journal:  Indian J Endocrinol Metab       Date:  2012-03

6.  Treatment of giant cell granuloma with intralesional corticosteroid injections: a case report.

Authors:  Ozlem Filiz Bayar; Gulsum Ak
Journal:  J Istanb Univ Fac Dent       Date:  2015-10-21

7.  Central giant cells lesion: Report of a conservative management.

Authors:  Marina Rolo Pinheiro da Rosa; Juliana Lopes de Sá; Valber Barbosa Martins; Marcelo Vinícius de Oliveira
Journal:  Eur J Dent       Date:  2018 Apr-Jun

8.  Intralesional corticosteroid injections in the treatment of central giant cell lesions of the jaws: a meta-analytic study.

Authors:  Rafael-Lima-Verde Osterne; Phelype-Maia Araújo; Abrahao-Cavalcante-Gomes de Souza-Carvalho; Roberta-Barroso Cavalcante; Eduardo Sant'Ana; Renato-Luiz-Maia Nongueira
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.